ClinicalTrials.gg
Active, not recruitingNCT03639701Updated Jan 28, 2026

Treatment of TK2 Deficiency With Thymidine and Deoxycytidine

A Phase 1/2 interventional study of Thymidine in Mitochondrial DNA Depletion Syndrome 2 Myopathic Type and Thymidine Kinase 2 Deficiency, sponsored by Columbia University. Active, not recruiting at 1 site in United States. Per ClinicalTrials.gov, last updated 2026-01-28.

Sponsored by Columbia University · Phase 1/2, Interventional, and Treatment

How we know

From the registry’s dates

  • Registered 1 year 2 months after the study started (first participant enrolled May 2017, registered Aug 2018).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
23
Allocation
Not applicable
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 83 studies in Mitochondrial Diseases with a site in United States — 20 open to participants now, 22 under way, 3 of them phase 3. Mitochondrial Diseases · United States.

Enrollment
34th of 50
23 · median 38
Started
2017
with 3 others
Phase 1/2
4 of 83
1 open now
Primary completion
2026-12
later than 1 of 21 live
Registered
54th of 83
by date
Lead sponsor
6 of 83
Columbia University

Among the 83 studies in Mitochondrial Diseases with a site in United States, this one is the 34th largest by enrollment of the 50 interventional ones that give a count, is one of 4 that started in 2017, is one of 4 in phase 1/2, reaches primary completion later than 1 of the 21 other live ones, and was the 54th registered.

Mitochondrial Diseases

189 studies on the registry are indexed under Mitochondrial Diseases; 60 are open to participants now.

Browse Mitochondrial Diseases studies →

Open to participants now

20 of the 83 studies in Mitochondrial Diseases with a site in United States are open now. Recruiting first, the newest first:

15 more — sign in →

All 20 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 41 Mitochondrial Diseases studies recruiting now, 20 (49%) set no upper age limit and 14 (34%) stop at 75 or younger; 19 take children under 18; 17 take healthy volunteers.

This study: all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 83 studies in Mitochondrial Diseases with a site in United States, or all of them as a file.
02

Study summary

Patients with confirmed mitochondrial DNA depletion syndrome 2 (thymidine kinase 2 [TK2] deficiency) have reduced levels of nucleotides (deoxythymidine monophosphate and deoxycytidine monophosphate) for mitochondrial DNA synthesis. This results in mitochondrial DNA depletion syndrome (i.e less number of functional mitochondrial DNA). Patients with confirmed TK2 deficiency will be treated with open label deoxythymidine (dThd) and deoxycytidine (dCyt), which are nucleotide precursors, with the expectation that the cells could make additional mitochondrial DNA. This in turn may help reduce the clinical symptoms.

Read the detailed description

Mitochondrial are responsible for the production of cellular energy. Mitochondria contain DNA which is the encoding system ( "recipe") for making the proteins that allow the mitochondria to function. Reduced amount of mitochondrial DNA, caused by genetic mutations in certain genes, Mitochondrial DNA Depletion Syndrome. This can result in symptoms; such as fatigue, weakness, and deficiencies in various body systems. TK2 deficiency is considered a mitochondrial depletion syndrome. Patients with TK2 deficiency have weakness and walking difficulty. They also have depleted levels of chemicals (phosphorylated deoxythymidine and deoxycytidine) used to make mitochondrial DNA. Based on previous studies with a similar compound, patients reported more energy and better motor skills.

Eligible patients include those with genetic mutations in the TK2 gene who are willing to attend several outpatient visits, and have motor skills testing, neurological exam by doctor, and blood samples.

03

Conditions studied

  • Mitochondrial DNA Depletion Syndrome 2 Myopathic Type
  • Thymidine Kinase 2 Deficiency

Keywords

  • Thymidine
  • Deoxycytidine
04

Who can participate

Ages eligible
Child (0–17), Adult (18–64), Older adult (65+)
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Genetically confirmed diagnosis of TK2 deficiency
  • Deemed by principle investigator to be symptomatic with TK2 deficiency
  • Single gene disease; absence of polygenic disease
  • Hematocrit within normal range for age group
  • Patient or patient's guardian able to consent and comply with protocol requirements
  • Presence of caregiver to ensure study compliance (if needed)
  • Abstention from use of all pill-form dietary supplements and non-prescribed medications (except as allowed by the investigator)
  • Abstention from use of other medications or other medications according to the study investigator

Exclusion criteria

Exclusion Criteria:

  • Clinical history of bleeding or abnormal (PT)/partial thromboplastin time (PTT)
  • Hepatic insufficiency with liver function tests (LFTs) greater than two times normal
  • Renal insufficiency requiring dialysis
  • Any other concurrent inborn errors of metabolism
  • Severe end-organ hypo-perfusion syndrome secondary to cardiac failure resulting in lactic acidosis
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
23 participants (actual)

Study arms

  • Experimental
    Open label thymidine and deoxycytidine

    All patients will receive open label thymidine and deoxycytidine

    Drug: Thymidine

Interventions

  • Mitochondrial DNA nucleotide precursors. Dose escalation: 130mg/kg/day x 14 days, 260 mg/kg/day x 14 days, and 400mg/kg/day as tolerated. Compounds are taken orally and divided into 3 doses daily.

    Also known as: Deoxycytidine

06

What researchers measure

Primary outcomes

  1. Alanine aminotransferase

    Number of participants with treatment-related elevated alanine aminotransferase (ALT) serum level relative to upper limit of normal (expressed as ratios) grade 3 or higher as defined by CTCAE 4.03.

    Time frame: Up to 60 months

  2. Aspartate aminotransferase

    Number of participants with treatment-related elevated aspartate aminotransferase (AST) serum level relative to upper limit of normal (expressed as ratios) grade 3 or higher as defined by CTCAE 4.03.

    Time frame: Up to 60 months

  3. Gamma-glutamyltransferase

    Number of participants with treatment-related elevated gamma-glutamyltransferase (GGT) serum level relative to upper limit of normal (expressed as ratios) grade 3 or higher as defined by CTCAE 4.03.

    Time frame: Up to 60 months

  4. Blood lymphocyte count

    Blood lymphocyte count increased relative to upper limit or normal or decreased relative to lower limit of normal (expressed as ratios) grade 3 or higher as defined by CTCAE 4.03.

    Time frame: Up to 60 months

  5. Creatinine

    Serum creatinine level increased relative to upper limit of normal (expressed as ratios) grade 3 or higher as defined by CTCAE 4.03.

    Time frame: Up to 60 months

  6. Electrocardiogram

    Number of patients with treatment related electrocardiogram (ECG) QT corrected interval (QTc) grade 3 or higher as defined by CTCAE version 4.03.

    Time frame: Up to 60 months

  7. Diarrhea

    Patient-Reported Outcome Measurement Information System (PROMIS) Scale v1.0 - Gastrointestinal Diarrhea 6a score (score range 0-30 with higher scores indicating more severe diarrhea)

    Time frame: Up to 60 months

Secondary outcomes

  1. Event-free survival

    Time to mechanical ventilation, death, or both will be assessed.

    Time frame: Up to 60 months

  2. 6-minute walk test

    Distance walked in meters over 6 minutes will be measured in ambulatory patient.

    Time frame: Up to 60 months

  3. Children's Hospital of Philadelphia Infant Test of Neuromuscular Disorders (CHOP INTEND)

    Children's Hospital of Philadelphia Infant Test of Neuromuscular Disorders (CHOP INTEND) score (0-64 point range with higher scores indicating better function) will be assessed in infants to assess motor function.

    Time frame: Up to 60 months

  4. Hammersmith Functional Motor Scale Expanded (HFMSE)

    Hammersmith Functional Motor Scale Expanded (HFMSE) score (0-66 point range with higher scores indicating better function) will be measured in subjects \>1 year-old.

    Time frame: Up to 60 months

  5. Vital Capacity

    Vital capacity (percent of predicted normal based on age and height) will be measure by spirometry

    Time frame: Up to 60 months

  6. Time on Mechanical Ventilation

    Number of hours per day that subjects use mechanical ventilation will be recorded.

    Time frame: Up to 60 months

  7. euro Quality of Life (Neuro-QoL) in adults

    Neuro Quality of Life (Neuro-QoL) short forms will be used to assess effects of muscle weakness on motor function and activities of daily living. In adults, Lower and Upper Extremity scales will be assessed (0-80 points with higher scores indicating better function).

    Time frame: Up to 60 months

  8. Neuro Quality of Life (Neuro-QoL) in pediatric subjects

    Neuro Quality of Life (Neuro-QoL) forms will be used to assess effects of muscle weakness on motor function and activities of daily living. In pediatric subjects (\<18 years-old), Lower and Upper Extremity scales will be assessed (0-160 points with higher scores indicating better function).

    Time frame: Up to 60 months

  9. Suicidal Ideation

    Suicidal ideation will be assessed by the Columbia-Suicide Severity Rating Scale (C-SSRS), which contains 6 "yes" or "no" questions. Answer of "yes" to any question indicates possible suicide risk and answer of "yes: to questions 4, 5, or 6 indicates high-risk.

    Time frame: Up to 60 months

07

Study locations

1 site
08

References and documents

Publications

  • Garone C, Taylor RW, Nascimento A, Poulton J, Fratter C, Dominguez-Gonzalez C, Evans JC, Loos M, Isohanni P, Suomalainen A, Ram D, Hughes MI, McFarland R, Barca E, Lopez Gomez C, Jayawant S, Thomas ND, Manzur AY, Kleinsteuber K, Martin MA, Kerr T, Gorman GS, Sommerville EW, Chinnery PF, Hofer M, Karch C, Ralph J, Camara Y, Madruga-Garrido M, Dominguez-Carral J, Ortez C, Emperador S, Montoya J, Chakrapani A, Kriger JF, Schoenaker R, Levin B, Thompson JLP, Long Y, Rahman S, Donati MA, DiMauro S, Hirano M. Retrospective natural history of thymidine kinase 2 deficiency. J Med Genet. 2018 Aug;55(8):515-521. doi: 10.1136/jmedgenet-2017-105012. Epub 2018 Mar 30. PubMed 29602790 ↗
  • Lopez-Gomez C, Levy RJ, Sanchez-Quintero MJ, Juanola-Falgarona M, Barca E, Garcia-Diaz B, Tadesse S, Garone C, Hirano M. Deoxycytidine and Deoxythymidine Treatment for Thymidine Kinase 2 Deficiency. Ann Neurol. 2017 May;81(5):641-652. doi: 10.1002/ana.24922. Epub 2017 May 4. PubMed 28318037 ↗
  • Garone C, Garcia-Diaz B, Emmanuele V, Lopez LC, Tadesse S, Akman HO, Tanji K, Quinzii CM, Hirano M. Deoxypyrimidine monophosphate bypass therapy for thymidine kinase 2 deficiency. EMBO Mol Med. 2014 Aug;6(8):1016-27. doi: 10.15252/emmm.201404092. PubMed 24968719 ↗
  • Chanprasert S, Wang J, Weng SW, Enns GM, Boue DR, Wong BL, Mendell JR, Perry DA, Sahenk Z, Craigen WJ, Alcala FJ, Pascual JM, Melancon S, Zhang VW, Scaglia F, Wong LJ. Molecular and clinical characterization of the myopathic form of mitochondrial DNA depletion syndrome caused by mutations in the thymidine kinase (TK2) gene. Mol Genet Metab. 2013 Sep-Oct;110(1-2):153-61. doi: 10.1016/j.ymgme.2013.07.009. Epub 2013 Jul 17. PubMed 23932787 ↗

Individual participant data

Plan to share: Undecided — Since there are very few patients in the world with TK2 Deficiency, we may share de-identified data with other researchers who are treating patients with TK2 Deficiency

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started May 2017 (actual). Primary completion is estimated for Dec 2026, 115 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 7, 2018
First posted
Aug 21, 2018
StartActual
May 16, 2017
Primary completionEst.
Dec 31, 2026
CompletionEst.
Dec 31, 2026
Last update
Jan 28, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 28, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03639701
Collaborators
Muscular Dystrophy Association, Hospital Universitario 12 de Octubre, Instituto de Salud Carlos III, University of Seville, Medical Research Council Mitochondrial Biology Unit, Consorcio Centro de Investigación Biomédica en Red (CIBER), Hospitales Universitarios Virgen del Rocío, Universitat Autonoma de Barcelona
Responsible party
Michio Hirano, MD (Professor of Neurology, Columbia University) — Principal investigator
First posted
Aug 21, 2018
Start date
May 16, 2017
Primary completion
Dec 31, 2026 (estimated)
Completion
Dec 31, 2026 (estimated)
Last update
Jan 28, 2026

Study contacts

Michio Hirano, MD
principal investigator · Columbia University

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Jan 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Thymidine

Start the discussion